Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2019 John Wiley & Sons, Ltd. Glucose-substituted ruthenium complexes [(η6-benzyl-glucose)RuCp*]+Cl−, where Cp* = η5-C5Me5; benzyl-glucose = peracetylated benzyl β-d-glucopyranoside (1), benzyl β-d-glucopyranoside (2), have been prepared and used as efficient antimigration and anti-invasive agents against metastatic breast cancer cells (MDA-MB-231) and cisplatin-resistant ovarian cancer cells (SK-OV-3). In addition, these complexes were found to be essentially non-toxic against non-cancerous human kidney cells (HEK293).

Original publication




Journal article


Applied Organometallic Chemistry

Publication Date